Cited by — Comparative effectiveness and safety of first-line anti-TNF, vedolizumab, and ustekinumab in biologic-naïve Crohn’s disease: Analysis from a real-world cohort | ResearchHub - ResearchHub
Research graph
Cited by
Admitted local publications that cite Comparative effectiveness and safety of first-line anti-TNF, vedolizumab, and ustekinumab in biologic-naïve Crohn’s disease: Analysis from a real-world cohort.
No admitted local citation edges point to this work yet.
